Summary
Innovative approaches to induce a strong immune response are key to the success of immunotherapy. Dendritic cells (DCs) are professional antigen-presenting cells (APCs) equipped with co-stimulatory, adhesion, and major histocompatibility complex (MHC) molecules needed for initiation and reactivation of the immune response. DCs are able to initiate and stimulate both innate and adaptive immune responses and, by secretion of cytokines, chemokines, and expression of regulatory molecules, to shape the adaptive immune response toward a long-lasting memory immunity. DCs from the peripheral blood of immune-compromised patients, however, often display an immature phenotype with defective functions. This emphasizes the importance and potential of engineering antigen-specific DCs in vitro. A state-of-the-art approach to overcome the prevailing immune dysfunction(s) in patients is to engineer DCs or DC progenitors to generate fully functional DCs for the modification of host immunity. Lentiviral vectors (LVs) are highly efficient gene transfer vehicles for engineering DC functions. Examples of lentiviral vectors encoding immune-modulatory genes and useful functional assays for the analysis of effector immune cell response are described in this chapter.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621–667.
Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LDJ. (1996) DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 2:1122–1128.
Liu M. (1998) Transfected human dendritic cells as cancer vaccines. Nat Biotechnol 16:335–336.
Chen X, He J, Chang L-J. (2004) Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells. Retrovirology 1:37.
Wang B, He J, Liu C, Chang LJ. (2006) An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens. Vaccine 24:3477–3489.
Ludewig B, Ehl S, Karrer U, Odermatt B, Hengartner H, Zinkernagel RM. (1998) Dendritic cells efficiently induce protective antiviral immunity. J Virol 72:3812–3818.
Kirk CJ, Mule JJ. (2000) Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 11:797–806.
Jenne L, Schuler G, Steinkasserer A. (2001) Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 22:102–107.
Murphy A, Westwood JA, Teng MW, Moeller M, Darcy PK, Kershaw MH. (2005) Gene modification strategies to induce tumor immunity. Immunity 22:403–414.
Breckpot K, Aerts JL, Thielemans K. (2007) Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther 14:847–862.
Lipscomb MF, Masten BJ. (2002) Dendritic cells: immune regulators in health and disease. Physiol Rev 82:97–130.
Mosmann TR, Coffman RL. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145–173.
Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. (1999) T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20:561–567.
Chambers CA. (2001) The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 22:217–223.
Chirathaworn C, Kohlmeier JE, Tibbetts SA, Rumsey LM, Chan MA, Benedict SH. (2002) Stimulation through intercellular adhesion molecule-1 provides a second signal for T cell activation. J Immunol 168:5530–5537.
Salomon B, Bluestone JA. (1998) LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production. J Immunol 161:5138–5142.
Sabatte J, Maggini J, Nahmod K, Amaral MM, Martinez D, Salamone G, Ceballos A,. (2007) Interplay of pathogens, cytokines and other stress signals in the regulation of dendritic cell function. Cytokine Growth Factor Rev 18:5–17.
Han S, Wang B, Cotter MJ, Yang LJ, Zucali J, Moreb JS, Chang LJ. (2008) Overcoming Immune Tolerance Against Multiple Myeloma With Lentiviral Calnexin-engineered Dendritic Cells. Mol Ther 16: 269–279.
Chang L-J, Zaiss A-K. (2001) Methods for the preparation and use of lentivirus vectors. In: Morgan J, ed. Gene Therapy Protocols, Vol. 2, 2nd ed. Humana Press, Totowa, NJ, 303–318.
Chang L-J, Zaiss A-K. (2001) Self inactivating lentiviral vectors in combination with a sensitive Cre/loxP reporter system. In: Walker J, ed. Methods in Molecular Medicine. Humana Press, Totowa, NJ, 367–382.
Lyons AB, Parish CR. (1994) Determination of lymphocyte division by flow cytometry. J Immunol Methods 171:131–137.
Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH. (2004) New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 103:2677–2682.
Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. (2003) Sensitive and viable identification of antigen-specific CD8 + T cells by a flow cytometric assay for degranulation. J Immunol Methods 281:65–78.
Hopken UE, Lehmann I, Droese J, Lipp M, Schuler T, Rehm A. (2005) The ratio between dendritic cells and T cells determines the outcome of their encounter: proliferation versus deletion. Eur J Immunol 35:2851–2863.
Mannering SI, Morris JS, Jensen KP, Purcell AW, Honeyman MC, van Endert PM, Harrison LC. (2003) A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J Immunol Methods 283:173–183.
Denkberg G, Cohen CJ, Reiter Y. (2001) Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR. J Immunol 167:270–276.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Han, S., Chang, LJ. (2009). Immunity of Lentiviral Vector-Modified Dendritic Cells. In: Walther, W., Stein, U. (eds) Gene Therapy of Cancer. Methods in Molecular Biology™, vol 542. Humana Press. https://doi.org/10.1007/978-1-59745-561-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-59745-561-9_13
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-934115-85-5
Online ISBN: 978-1-59745-561-9
eBook Packages: Springer Protocols